Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 57.27

+1.0%

11:31 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biotech Jim who wrote (8817)	7/14/2003 12:06:24 AM
From: Miljenko Zuanic	Read Replies (1) of 52153

Jim, so far we do not have evidence that trp-p8 calcium channel is important for metastatic PC, regardless that is over-expressed. Second, can one develop effective vaccines or antibody for this large tetramer protein? Regards the Provenge, follow DNDN slides and compare PLACEBO for <7 and >8 sub-population. Provenge did better for first one ONLY because <7-PLACEBO done worse than >8. Not that Provenge done better for <7 than >8. Which is contradictory to what they are proposing. So, I will not give Provenge more that 20% chance for effective PC trial. Regards the PC, MLNM conjugate may be sufficiently specific for PC, and effective. But, first I would like to see some hard data before get excited. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next